Can this new Antibody-Drug Conjugate Collaboration make it to the Top?

26/10/2016 - 2 minutes

Nordic Nanovector is collaborating with Heidelberg Pharma to access the promising antibody-drug conjugate (ADC) technology. However, can it really take on the strong competition?

logoNordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat Non-Hodgkin Lymphoma (NHL) and other blood cancers. Today, the company has announced a collaboration with Wilex’ subsidiary Heidelberg Pharma to incorporate antibody-drug conjugates (ADCs) for leukemia in its pipeline.

The ARC and ADC technologies are similar: a tumor-specific antibody is chemically linked to a molecule that kills the target cell. However, ADCs seem to be way more popular, presumably because they’re effective against a wider range of tumors than ARCs. The main difference is that ARCs are linked to a molecule that emits beta radiation, whereas ADCs carry a toxin that interacts with intracellular molecules.

Nordic Nanovector’s lead ARC candidate, Betalutin (lilotomab), is proving safe and effective in Phase I/II trials for NHL. With this move into the more popular ADCs, the company plans to sum the leukemia market, which is expected to reach over €5B by 2020,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member